Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program ...
13:23 EDT 30 Jun 2012 | LaMerie
-- Biogen Idec has Option to Develop and Commercialize Promising Compound for Most Common Form of Muscular Dystrophy --
--Isis Expands its Rare Disease Franchise to Include Myotonic Dystrophy Type 1--
Original Article: Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program ...
More From BioPortfolio on "Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program ..."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
